Broadcast Date: 
  • Time: 

The transplantation of donor cells into a patient for the purposes of treating or curing disease lies at the core of the cell therapy endeavors. Advances in cell and molecular biology have opened new avenues of research once thought out of reach for many investigators—lending to the possibility of developing unimagined therapies, even cures, for severe health disorders.

In this webinar from The CRISPR Journal and GEN, Dr. T.J. Cradick—who was until recently head of genome editing at CRISPR Therapeutics—will introduce how genome editing is used to engineer cell therapies. Several types of cell therapies and their application toward specific disease indications will be demonstrated, including both traditional and current clinical cell therapies. Autogenic, allogeneic, and xenogeneic therapies will be introduced. Autogenic and “off-the-shelf” allogeneic CAR-T cell therapies will be further compared.

Additionally, Dr. Cradick will compare the types of editing that can be used to knock-out or knock-in genes and/or correct sequences. Combinations of these strategies will also be shown in multiplex, advanced editing. Examples will include uses of CRISPR nucleases, and more recently developed technologies, base editing, and prime editing. Critical assays and parameters for curative cell therapy will also be discussed.

This is the second in a series of three webinars on Genome Editing and Cell Therapies sponsored by TriLink BioTechnologies.

Produced with support from:

TriLink Leading the way
TJ Cradick, PhD
T.J. Cradick, PhD
Consultant and Advisor
Gene & Cell Therapy and Bioinformatics